Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum
A Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of the Rectum
Sponsor: Bristol-Myers Squibb
Terminated
Loss of funding
Other terminated trials from Bristol-Myers Squibb
Other Rectal Cancer trials with similar outcome
Listed as NCT00580073, this PHASE2 trial focuses on Rectal Cancer and remains terminated or withdrawn. Sponsored by Bristol-Myers Squibb, it has been updated 12 times since 2007, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Nov 2019 — Jan 2020 [monthly]
Terminated PHASE2
-
Jun 2018 — Nov 2019 [monthly]
Terminated PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Feb 2017 — Jun 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Dec 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Eli Lilly and Company
- Sanofi
- University of Wisconsin, Madison
For direct contact, visit the study record on ClinicalTrials.gov .